Oncology Reviews最新文献_第5页

Programmed death ligand-1 protein expression difference in basal like and non-basal like triple negative breast cancer and its association with disease free survival and overall survival: A systematic review. 程序性死亡配体-1蛋白在基底样和非基底样三阴性乳腺癌中的表达差异及其与无病生存期和总生存期的关系:一项系统综述

IF 3.6

Oncology Reviews Pub Date : 2021-09-28 eCollection Date: 2021-09-21 DOI: 10.4081/oncol.2021.533

Freda Halim, Hasrayati Agustina, Yohana Azhar, Bethy Hernowo

{"title":"Programmed death ligand-1 protein expression difference in basal like and non-basal like triple negative breast cancer and its association with disease free survival and overall survival: A systematic review.","authors":"Freda Halim, Hasrayati Agustina, Yohana Azhar, Bethy Hernowo","doi":"10.4081/oncol.2021.533","DOIUrl":"https://doi.org/10.4081/oncol.2021.533","url":null,"abstract":"The study aims to summarize the literature and explore the strength of evidence for PD-L1 expression difference in basal like TNBC and non-basal like TNBC, and association of PD-L1 expression with disease free survival and overall survival in each group. A systematic search of the original research literature through November 29th, 2020, reported according to PRISMA guideline. Eligible studies investigated must have a primary outcome and at least one secondary outcome. Two reviewers independently searched, selected, and assessed quality of studies and risk of bias. Any discrepancies will be resolved by consensus or by consulting a third and fourth author. A total of 6813 articles were screened from which five articles were selected and assessed for quality of studies and risk of bias. Of 5 articles, no similar findings are found regarding the level of PD-L1 expression and its correlation with recurrence and overall survival. There is not enough substantial evidence to support the difference PD-L1 protein expression level in basal and non-basal like TNBC and its association with recurrence and overall survival. Hence, further studies are needed specifically to focus on this problem.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"15 2","pages":"533"},"PeriodicalIF":3.6,"publicationDate":"2021-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/07/4e/onco-15-2-533.PMC8491008.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39561284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC? 多纳非尼在中国晚期肝细胞癌(HCC)患者中的应用:真的是一个新的治疗标准，还是我们应该改变HCC药物开发的模式?

IF 3.6

Oncology Reviews Pub Date : 2021-09-22 eCollection Date: 2021-09-21 DOI: 10.4081/oncol.2021.564

Francesca Negri, Camillo Porta

引用次数: 4

Molecular insights and clinical impacts of extracellular vesicles in cancer. 细胞外囊泡在癌症中的分子见解和临床影响。

IF 3.6

Oncology Reviews Pub Date : 2021-09-21 DOI: 10.4081/oncol.2021.542

Kittinun Leetanaporn, Jitti Hanprasertpong, Raphatphorn Navakanitworakul

引用次数: 1

The repair gene BACH1 - a potential oncogene. 修复基因BACH1 -一个潜在的致癌基因。

IF 3.6

Oncology Reviews Pub Date : 2021-07-02 eCollection Date: 2021-02-26 DOI: 10.4081/oncol.2021.519

Katheeja Muhseena N, Sooraj Mathukkada, Shankar Prasad Das, Suparna Laha

{"title":"The repair gene BACH1 - a potential oncogene.","authors":"Katheeja Muhseena N, Sooraj Mathukkada, Shankar Prasad Das, Suparna Laha","doi":"10.4081/oncol.2021.519","DOIUrl":"https://doi.org/10.4081/oncol.2021.519","url":null,"abstract":"BACH1 encodes for a protein that belongs to RecQ DEAH helicase family and interacts with the BRCT repeats of BRCA1. The N-terminus of BACH1 functions in DNA metabolism as DNA-dependent ATPase and helicase. The C-terminus consists of BRCT domain, which interacts with BRCA1 and this interaction is one of the major regulator of BACH1 function. BACH1 plays important roles both in phosphorylated as well as dephosphorylated state and functions in coordination with multiple signaling molecules. The active helicase property of BACH1 is maintained by its dephosphorylated state. Imbalance between these two states enhances the development and progression of the diseased condition. Currently BACH1 is known as a tumor suppressor gene based on the presence of its clinically relevant mutations in different cancers. Through this review we have justified it to be named as an oncogene. In this review, we have explained the mechanism of how BACH1 in collaboration with BRCA1 or independently regulates various pathways like cell cycle progression, DNA replication during both normal and stressed situation, recombination and repair of damaged DNA, chromatin remodeling and epigenetic modifications. Mutation and overexpression of BACH1 are significantly found in different cancer types. This review enlists the molecular players which interact with BACH1 to regulate DNA metabolic functions, thereby revealing its potential for cancer therapeutics. We have identified the most mutated functional domain of BACH1, the hot spot for tumorigenesis, justifying it as a target molecule in different cancer types for therapeutics. BACH1 has high potentials of transforming a normal cell into a tumor cell if compromised under certain circumstances. Thus, through this review, we justify BACH1 as an oncogene along with the existing role of being a tumor suppressant.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"15 1","pages":"519"},"PeriodicalIF":3.6,"publicationDate":"2021-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/06/10/onco-15-1-519.PMC8273628.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39254643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity! 扩大对乳腺癌生殖系致病变异的研究。我们应该走多远，跳多高?错失的机会!

IF 3.6

Oncology Reviews Pub Date : 2021-06-24 eCollection Date: 2021-02-26 DOI: 10.4081/oncol.2021.544

Hikmat Abdel-Razeq

引用次数: 3

Adenomatous polyposis coli in cancer and therapeutic implications. 腺瘤性大肠息肉病在癌症和治疗意义。

IF 3.6

Oncology Reviews Pub Date : 2021-06-24 eCollection Date: 2021-02-26 DOI: 10.4081/oncol.2021.534

Olivia Noe, Louis Filipiak, Rachel Royfman, Austin Campbell, Leslie Lin, Danae Hamouda, Laura Stanbery, John Nemunaitis

{"title":"Adenomatous polyposis coli in cancer and therapeutic implications.","authors":"Olivia Noe, Louis Filipiak, Rachel Royfman, Austin Campbell, Leslie Lin, Danae Hamouda, Laura Stanbery, John Nemunaitis","doi":"10.4081/oncol.2021.534","DOIUrl":"https://doi.org/10.4081/oncol.2021.534","url":null,"abstract":"Inactivating mutations of the adenomatous polyposis coli (APC) gene and consequential upregulation of the Wnt signaling pathway are critical initiators in the development of colorectal cancer (CRC), the third most common cancer in the United States for both men and women. Emerging evidence suggests APCmutations are also found in gastric, breast and other cancers. The APC gene, located on chromosome 5q, is responsible for negatively regulating the b-catenin/Wnt pathway by creating a destruction complex with Axin/Axin2, GSK-3b, and CK1. In the event of an APC mutation, b-catenin accumulates, translocates to the cell nucleus and increases the transcription of Wnt target genes that have carcinogenic consequences in gastrointestinal epithelial stem cells. A literature review was conducted to highlight carcinogenesis related to APC mutations, as well as preclinical and clinical studies for potential therapies that target steps in inflammatory pathways, including IL-6 transduction, and Wnt pathway signaling regulation. Although a range of molecular targets have been explored in murine models, relatively few pharmacological agents have led to substantial increases in survival for patients with colorectal cancer clinically. This article reviews a range of molecular targets that may be efficacious targets for tumors with APC mutations.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"15 1","pages":"534"},"PeriodicalIF":3.6,"publicationDate":"2021-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0a/13/onco-15-1-534.PMC8256374.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39189003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Published randomized controlled trials of surveillance in cancer patients - a systematic review. 已发表的癌症患者监测随机对照试验--系统回顾。

IF 3.1

Oncology Reviews Pub Date : 2021-06-24 eCollection Date: 2021-02-26 DOI: 10.4081/oncol.2021.522

Victoria Giglio, Patricia Schneider, Kim Madden, Bill Lin, Iqbal Multani, Hassan Baldawi, Patrick Thornley, Leen Naji, Marc Levin, Peiyao Wang, Anthony Bozzo, David Wilson, Michelle Ghert

{"title":"Published randomized controlled trials of surveillance in cancer patients - a systematic review.","authors":"Victoria Giglio, Patricia Schneider, Kim Madden, Bill Lin, Iqbal Multani, Hassan Baldawi, Patrick Thornley, Leen Naji, Marc Levin, Peiyao Wang, Anthony Bozzo, David Wilson, Michelle Ghert","doi":"10.4081/oncol.2021.522","DOIUrl":"10.4081/oncol.2021.522","url":null,"abstract":"With solid tumor cancer survivorship increasing, the number of patients requiring post-treatment surveillance also continues to increase. This highlights the need for evidence-based cancer surveillance guidelines. Ideally, these guidelines would be based on combined high-quality data from randomized controlled trials (RCTs). We present a systematic review of published cancer surveillance RCTs in which we sought to determine the feasibility of data pooling for guideline development. We carried out a systematic search of medical databases for RCTs in which adult patients with solid tumors that had undergone surgical resection with curative intent and had no metastatic disease at presentation, were randomized to different surveillance regimens that assessed effectiveness on overall survival (OS). We extracted study characteristics and primary and secondary outcomes, and assessed risk of bias and validity of evidence with standardized checklist tools. Our search yielded 32,216 articles for review and 18 distinct RCTs were included in the systematic review. The 18 trials resulted in 23 comparisons of surveillance regimens. There was a highlevel of variation between RCTs, including the study populations evaluated, interventions assessed and follow-up periods for the primary outcome. Most studies evaluated colorectal cancer patients (11/18, [61%]). The risk of bias and validity of evidence were variable and inconsistent across studies. This review demonstrated that there is tremendous heterogeneity among RCTs that evaluate effectiveness of different postoperative surveillance regimens in cancer patients, rendering the consolidation of data to inform high-quality cancer surveillance guidelines unfeasible. Future RCTs in the field should focus on consistent methodology and primary outcome definition.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"15 1","pages":"522"},"PeriodicalIF":3.1,"publicationDate":"2021-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/48/88/onco-15-1-522.PMC8256375.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39189014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pre-clinical modelling of rectal cancer to develop novel radiotherapy-based treatment strategies. 建立直肠癌临床前模型，开发基于放射治疗的新型治疗策略。

IF 3.6

Oncology Reviews Pub Date : 2021-06-18 eCollection Date: 2021-02-26 DOI: 10.4081/oncol.2021.511

Michael A Gillespie, Colin W Steele, Tamsin R M Lannagan, Owen J Sansom, Campbell S D Roxburgh

{"title":"Pre-clinical modelling of rectal cancer to develop novel radiotherapy-based treatment strategies.","authors":"Michael A Gillespie, Colin W Steele, Tamsin R M Lannagan, Owen J Sansom, Campbell S D Roxburgh","doi":"10.4081/oncol.2021.511","DOIUrl":"10.4081/oncol.2021.511","url":null,"abstract":"Pre-operative chemoradiotherapy reduces local recurrence rates in locally advanced rectal cancer. 10-20% of patients undergo complete response to chemoradiotherapy, however, many patients show no response. The mechanisms underlying this are poorly understood; identifying molecular and immunological factors underpinning heterogeneous responses to chemoradiotherapy, will promote development of treatment strategies to improve responses and overcome resistance mechanisms. This review describes the advances made in pre-clinical modelling of colorectal cancer, including genetically engineered mouse models, transplantation models, patient derived organoids and radiotherapy platforms to study responses to chemoradiotherapy. Relevant literature was identified through the PubMed and MEDLINE databases, using the following keywords: rectal cancer; mouse models; organoids; neo-adjuvant treatment; radiotherapy; chemotherapy. By delineating the advantages and disadvantages of available models, we discuss how modelling techniques can be utilized to address current research priorities in locally advanced rectal cancer. We provide unique insight into the potential application of pre-clinical models in the development of novel neo-adjuvant treatment strategies, which will hopefully guide future clinical trials.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"15 1","pages":"511"},"PeriodicalIF":3.6,"publicationDate":"2021-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6d/c1/onco-15-1-511.PMC8237517.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39173891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Roles of regulator of chromosome condensation 2 in cancer: Beyond its regulatory function in cell cycle. 染色体凝聚2在癌症中的调节作用:超越其在细胞周期中的调节功能。

IF 3.6

Oncology Reviews Pub Date : 2021-03-19 eCollection Date: 2021-02-26 DOI: 10.4081/oncol.2021.525

Ali Calderon-Aparicio, Ann M Bode

{"title":"Roles of regulator of chromosome condensation 2 in cancer: Beyond its regulatory function in cell cycle.","authors":"Ali Calderon-Aparicio, Ann M Bode","doi":"10.4081/oncol.2021.525","DOIUrl":"https://doi.org/10.4081/oncol.2021.525","url":null,"abstract":"Regulator of chromosome condensation 2 (RCC2) is an essential protein in order for mitosis to proceed properly. It localizes in the centrosome of chromosomes where is involved in chromosome segregation and cytokinesis. Furthermore, RCC2 associates with integrin networks at the plasma membrane where participates in the control of cell movement. Because of its known role in cell cycle, RCC2 has been linked with cancer progression. Several reports show that RCC2 induces cancer hallmarks, but the mechanisms explaining how RCC2 exerts these roles are widely unknown. Here, we aim to summarize the main findings explaining the roles and mechanisms of RCC2 in cancer promotion. RCC2 is overexpressed in different cancers, including glioblastoma, lung, ovarian, and esophageal which is related to proliferation, migration, invasion promotion in vitro and tumor progression and metastasis in vivo. Besides, RCC2 overexpression induces epithelial-mesenchymal transition and causes poorer prognosis in cancer patients. RCC2 overexpression has also been linked with resistance development to chemotherapy and radiotherapy by inhibiting apoptosis and activating cancer-promoting transcription factors. Unfortunately, not RCC2 inhibitors are currently available for further pre-clinical and clinical assays. Therefore, these findings emphasize the potential use of RCC2 as a targetable biomarker in cancer and highlight the importance for designing RCC2 chemical inhibitors to evaluate its efficacy in animal studies and clinical trials.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"15 1","pages":"525"},"PeriodicalIF":3.6,"publicationDate":"2021-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/41/32/onco-15-1-525.PMC8018209.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25565722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Adjunctive treatment of myxopapillary ependymoma. 肌乳头状上皮瘤的辅助治疗。

IF 3.6

Oncology Reviews Pub Date : 2021-03-17 eCollection Date: 2021-02-26 DOI: 10.4081/oncol.2021.518

Amin Jahanbakhshi, Masoumeh Najafi, Fatemeh Jafari, Mahsa Moshtaghian, Marzieh Gomar, Mousareza Anbarlouei, Soheil Naderi

{"title":"Adjunctive treatment of myxopapillary ependymoma.","authors":"Amin Jahanbakhshi, Masoumeh Najafi, Fatemeh Jafari, Mahsa Moshtaghian, Marzieh Gomar, Mousareza Anbarlouei, Soheil Naderi","doi":"10.4081/oncol.2021.518","DOIUrl":"10.4081/oncol.2021.518","url":null,"abstract":"Myxopapillary ependymoma are rare tumors and optimal therapeutic strategy is remained controversial. The main treatments for myxopapillary ependymoma tumors include surgery and radiotherapy. Hence, the present study aimed to review adjuvant treatment of myxopapillary ependymoma, focusing on spinal myxopapillary ependymoma. The information sources of all articles were the English authoritative databases including PubMed, Web of science, Scopus, Science direct and Google scholar. In this review study, the keywords including adjuvant, treatment, myxopapillary and ependymoma were selected from MeSH medical library. Related articles were published from 2000 to 2020. Given radiation tolerance in the spinal cord is 10-15% lower than that of the brain, it also should be noted that with increased dose and scope of therapeutic field, the corresponding risks are increased, as well. Also, chemotherapy has never been used as the primary treatment approach. Radiotherapy's value is considered while involving with sensitive areas where chemotherapy is also recommended. Gross total resection is the preferred primary treatment. But the role of adjuvant radiotherapy is debated in different tumor and patient scenarios and no standard treatment strategy had been defined yet. The bottom line is that as long as cellular and molecular methods or gene therapy can be used in the treatment of myxopapillary ependymoma, all the studies confirm that the best treatment method is still wide surgical resection as much as possible.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"15 1","pages":"518"},"PeriodicalIF":3.6,"publicationDate":"2021-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/54/74/onco-15-1-518.PMC8018208.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25565723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0